地奥心血康胶囊联合地尔硫卓对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响分析

doi:10.3760/cma.j.cn441417-20241128-11006

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (11): 1791-1795.DOI: 10.3760/cma.j.cn441417-20241128-11006

地奥心血康胶囊联合地尔硫卓对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响分析

金兴山¹ 杨莉²

¹驻马店市第一人民医院心血管内科，驻马店 463000；²驻马店市中医院河南中医药大学第六临床医学院康复医学科，驻马店 463000

收稿日期:2024-11-28 出版日期:2025-06-01 发布日期:2025-06-12
通讯作者: 金兴山，Email：15290192604@163.com
基金资助:
2024年度河南省中医药科学研究专项课题（2024ZY2206）

Analysis of the effects of Di'ao Xinxuekang Capsules combined with diltiazem on clinical symptoms and serum cytokine levels in patients with angina pectoris of coronary heart disease

Jin Xingshan¹, Yang Li²

¹Department of Cardiovascular Medicine, The First People's Hospital of Zhumadian, Zhumadian 463000, China; ²Department of Rehabilitation Medicine, Zhumadian TCM Hospital, The Sixth Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhumadian 463000, China

Received:2024-11-28 Online:2025-06-01 Published:2025-06-12
Contact: Jin Xingshan, Email: 15290192604@163.com
Supported by:
Special Subject of TCM Scientific Research in Henan Province in 2024 (2024ZY2206)

摘要/Abstract

摘要：

目的　分析地奥心血康胶囊联合地尔硫卓治疗冠心病心绞痛的效果。方法　选取2022年3月至2024年7月驻马店市第一人民医院收治的96例冠心病心绞痛患者作为研究对象。按照治疗方案，将患者分为对照组（49例）和研究组（47例）。对照组男20例，女29例；年龄54～70（61.97±3.35）岁；病程5～15（10.24±1.96）个月。研究组男19例，女28例；年龄53～70（62.08±3.46）岁；病程5～16（10.31±1.89）个月。对照组采用地尔硫卓治疗，研究组在对照组基础上联合地奥心血康胶囊治疗。两组均持续治疗3个月。比较两组治疗效果和不良反应，治疗前后临床症状（心绞痛发作频次、持续时间）、心功能［左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）］、血清相关细胞因子水平［血清N末端B型利钠肽原（NT-proBNP）、心肌肌钙蛋白I（cTnI）、超敏C反应蛋白（hs-CRP）水平以及中性粒细胞和淋巴细胞比值（NLR）］。采用独立样本t检验、配对t检验和χ²检验进行统计学分析。结果　研究组治疗总有效率高于对照组［95.75%（45/47）比77.55%（38/49）］（P<0.05）。治疗后，研究组心绞痛发作频次少于对照组［（2.30±0.49）次/周比（3.22±0.51）次/周］，持续时间短于对照组［（3.22±0.71）min/次比（4.61±0.85）min/次］（均P<0.05）；研究组LVEF高于对照组［（48.02±0.61）%比（45.91±0.52）%］，LVESD小于对照组［（40.15±2.98）mm比（44.05±3.07）mm］（均P<0.05）；研究组血清NT-proBNP、cTnI、hs-CRP水平和NLR均低于对照组［（246.51±29.52）ng/L比（378.54±31.74）ng/L、（0.20±0.04）μg/L比（0.39±0.05）μg/L、（3.05±0.74）mg/L比（4.65±0.92）mg/L、1.98±0.35比2.61±0.39］（均P<0.05）。两组不良反应总发生率比较，差异无统计学意义（P>0.05）。结论　地奥心血康胶囊联合地尔硫卓治疗冠心病心绞痛效果较好，可抑制心绞痛发作、炎症反应，改善心功能，减轻心肌受损程度，安全性较好。

关键词:

冠心病, 心绞痛, 地奥心血康胶囊, 地尔硫卓

Abstract:

Objective　To analyze the efficacy of Di'ao Xinxuekang Capsules combined with diltiazem in the treatment of angina pectoris of coronary heart disease. Methods　A total of 96 patients with angina pectoris of coronary heart disease who were admitted to the First People's Hospital of Zhumadian from March 2022 to July 2024 were selected as the study subjects. According to the treatment plan, the patients were divided into the control group (49 cases) and the study group (47 cases). There were 20 males and 29 females in the control group, aged 54-70 (61.97±3.35) years, course of the disease 5-15 (10.24±1.96) months. There were 19 males and 28 females in the study group, aged 53-70 (62.08±3.46) years, course of the disease 5-16 (10.31±1.89) months. The control group was treated with diltiazem, while the study group was treated with Di'ao Xinxuekang capsules in addition to the treatment of the control group. Both groups received continuous treatment for 3 months. Compare the therapeutic effects and adverse reactions of the two groups, as well as the clinical symptoms (frequency and duration of angina pectoris attacks), cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD)], and levels of serum-related cytokines [serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP) levels, and the ratio of neutrophils to lymphocytes (NLR)] before and after treatment. Independent sample t test, paired t test, and χ² test were used for statistical analysis. Results　The total effective rate of the study group was higher than that of the control group [95.75% (45/47) vs. 77.55% (38/49)] (P<0.05). After treatment, the frequency of angina pectoris attacks in the study group was lower than that in the control group [(2.30±0.49) times/week vs. (3.22±0.51) times/week], and the duration was shorter than that in the control group [(3.22±0.71) min/time vs. (4.61±0.85) min/time] (both P<0.05); the LVEF of the study group was higher than that of the control group [(48.02±0.61)% vs. (45.91±0.52)%], and the LVESD was lower than that of the control group [(40.15±2.98) mm vs. (44.05±3.07) mm] (both P<0.05); the levels of serum NT-proBNP, cTnI, hs-CRP and NLR in the study group were all lower than those in the control group [(246.51±29.52) ng/L vs. (378.54±31.74) ng/L, (0.20±0.04) μg/L vs. (0.39±0.05) μg/L, (3.05±0.74) mg/L vs. (4.65±0.92) mg/L, 1.98±0.35 vs. 2.61±0.39] (all P<0.05). The comparison of the total incidence rates of adverse reactions between the two groups showed no statistically significant difference (P>0.05). Conclusion　The combination of Di'ao Xinxuekang Capsules and diltiazem is effective in treating angina pectoris of coronary heart disease. It can inhibit the occurrence of angina pectoris, reduce inflammatory responses, improve cardiac function, and alleviate the degree of myocardial damage. It also has good safety.

Key words: Coronary heart disease, Angina pectoris, Di'ao XinxuekangCapsules, Diltiazem

金兴山杨莉.

地奥心血康胶囊联合地尔硫卓对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响分析 [J]. 国际医药卫生导报, 2025, 31(11): 1791-1795.

Jin Xingshan, Yang Li.

Analysis of the effects of Di'ao Xinxuekang Capsules combined with diltiazem on clinical symptoms and serum cytokine levels in patients with angina pectoris of coronary heart disease [J]. International Medicine and Health Guidance News, 2025, 31(11): 1791-1795.

参考文献

[1]Dhar I, Svingen GF, Bjørnestad EØ, et al. B-vitamin treatment modifies the mortality risk associated with calcium channel blockers in patients with suspected stable angina pectoris: a prospective cohort study[J]. Am J Clin Nutr, 2023, 118(1):77-84. DOI: 10.1016/j.ajcnut.2023.04.033.

[2]李鹏,逯金金,李宇轩,等.基于CiteSpace和VOSviewer对补阳还五汤治疗冠心病心绞痛研究热点趋势可视化分析[J].中国医药导报,2023,20(23):139-143.DOI:10.20047/j.issn1673-7210.2023.23.30.

[3]张富山,张宇,蔡俊,等.地尔硫卓对冠心病心绞痛患者冠状动脉血流储备与血管内皮的影响[J].中国循证心血管医学杂志,2023,15(3):325-328.DOI:10.3969/j.issn.1674-4055.2023.03.17.

[4]陈志恒,张燕霞,刘正丽.不同剂量替罗非班联合地尔硫卓对高危不稳定型心绞痛近期和远期预后的影响[J].实用临床医药杂志,2022,26(20):110-113,118.DOI:10.7619/jcmp.20221632.

[5]吴积团,胡根生,汤文天,等.地奥心血康胶囊联合阿托伐他汀治疗稳定型心绞痛的临床研究[J].现代药物与临床,2024,39(3):642-646.DOI:10.7501/j.issn.1674-5515. 2024.03.016.

[6]赵泓渊,杨丹,杨茂琼,等.地奥心血康软胶囊联合富马酸比索洛尔片治疗劳力型心绞痛的临床效果研究[J].中国医药,2024,19(1):11-14.DOI:10.3760/j.issn.1673-4777. 2024.01.003.

[7]罗茜,尹紫薇,周颖丽,等.常规西药联合地奥心血康胶囊治疗冠心病的有效性和安全性分析[J].湖南中医杂志,2024,40(5):126-132.DOI:10.16808/j.cnki.issn1003-7705. 2024.05.033.

[8]胡元斌,吕娇.地奥心血康胶囊联合氯吡格雷在冠心病心绞痛患者中的应用[J].实用中西医结合临床,2023,23(21):78-80,94.DOI:10.13638/j.issn.1671-4040.2023.21.021.

[9]国家中医药管理局.中医病证诊断疗效标准:ZY/T001.1～001.9—94[S].南京:南京大学出版社,1994:29-30.

[10]Ferrari R, Camici PG, Crea F, et al. Expert consensus document: a 'diamond' approach to personalized treatment of angina[J]. Nat Rev Cardiol, 2018, 15(2):120-132. DOI: 10.1038/nrcardio.2017.131.

[11]李世阁,张晓丹.麝香保心丸联合地奥心血康治疗冠心病心绞痛的临床疗效观察[J].航空航天医学杂志,2023,34(4):453-455.DOI:10.3969/j.issn.2095-1434.2023.04.025.

[12]中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2022概要[J].心脑血管病防治,2023,23(7):1-19,24.DOI:10.3969/j.issn.1009-816x.2023.07.001.

[13]于鲁,李珠,王朔,等.血府逐瘀胶囊对冠心病心绞痛患者西雅图心绞痛量表评分影响的多中心前瞻性队列研究[J].中医杂志,2023,64(2):146-152.DOI:10.13288/j.11-2166/r.2023.02.008.

[14]施长琪,王莹威.益气活血通脉法治疗冠心病心绞痛(气虚血瘀证)的临床疗效及对RDW影响的临床研究[J].中医药学报,2023,51(4):89-93.DOI:10.19664/j.cnki.1002- 2392 .230086.

[15]李晓颖,孙东霞,许雅妮,等.冠心宁片治疗冠心病心绞痛的Meta分析及GRADE证据评价[J].中国中药杂志,2023,48(1):247-255.DOI:10.19540/j.cnki.cjcmm. 20221015.501.

[16]仝艳琼,吴刚.富马酸比索洛尔联合地尔硫卓对冠心病心绞痛患者心绞痛发作情况及血管内皮功能的影响[J].反射疗法与康复医学,2024,5(7):107-109.

[17]凌格,姚茂篪,叶玉昌,等.心可舒片联合盐酸地尔硫卓片治疗老年冠心病心绞痛的临床研究[J].现代生物医学进展,2023,23(19):3749-3753.DOI:10.13241/j.cnki.pmb.2023.19.030.

[18]李梦媛,曹兆流,鲍柏屹.地奥心血康联合钙通道阻滞剂治疗冠心病心绞痛患者疗效的Meta分析[J].中国循证心血管医学杂志,2023,15(7):777-780,792.DOI:10.3969/j.issn.1674-4055.2023.07.02.

[19]石小平,赵飞.丹参注射液联合地奥心血康胶囊治疗冠状动脉粥样硬化性心脏病心绞痛临床研究[J].中国药业,2023,32(9):98-102.DOI:10.3969/j.issn.1006-4931. 2023.09.023.

[20]赵忠平,刘虎,盛红专.HDL-C/ApoA1、MCP-1水平与中青年冠心病患者病变程度及炎症反应的相关性[J].中国现代医学杂志,2023,33(16):49-54.DOI:10.3969/j.issn.1005- 8982. 2023.16.009.

[21]刘佩,肖晓霞,王勇,等.MHR、NLR及GPR在不稳定型心绞痛患者中的水平及与冠状动脉病变程度的关系[J].疑难病杂志,2023,22(8):835-838,844.DOI:10.3969/j.issn.1671-6450.2023.08.009.

[22]施颖超,杨浩,张小英.血清超敏C-反应蛋白及肌钙蛋白I与老年冠心病的相关性研究[J].中国现代医生,2021,59(33):27-30.

[23]王超.不稳定型心绞痛患者心电图变化与cTnⅠ的相关性研究[J].罕少疾病杂志,2022,29(6):66-67,109.DOI:10.3969/j.issn.1009-3257.2022.06.024.

[24]王伟丽,胡成燕,贾美雪.冠心病心绞痛患者临床特点及不良心血管事件发生的危险因素分析[J].中国循证心血管医学杂志,2023,15(12):1350-1352.DOI:10.3969/j.issn.1674-4055.2023.12.16.

[25]蔡春生,孙晓净,代聚平.地奥心血康胶囊联合瑞舒伐他汀钙片治疗急性心肌梗死患者的效果观察[J].临床医学工程,2023,30(12):1673-1674.DOI:10.3969/j.issn.1674-4659. 2023.12.1673.

地奥心血康胶囊联合地尔硫卓对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响分析

Analysis of the effects of Di'ao Xinxuekang Capsules combined with diltiazem on clinical symptoms and serum cytokine levels in patients with angina pectoris of coronary heart disease

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	臧柯靓班芳张秋梅张恒亮. 香丹注射液联合酒石酸美托洛尔对冠心病心绞痛患者临床症状及氧化应激反应的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1520-1524.
[2]	韩鑫盛杰鑫任琳子于杰. 预测冠心病患者心肌缺血事件的冠状动脉CT血管成像定量参数分析 [J]. 国际医药卫生导报, 2025, 31(3): 365-370.
[3]	刘功艳王琳李传波韩克丽. 尼可地尔联合胺碘酮对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响 [J]. 国际医药卫生导报, 2025, 31(3): 382-386.
[4]	刘谊韩宝华张悦. 黄芪宗气方治疗冠心病合并心力衰竭患者的效果及对血管内皮功能影响 [J]. 国际医药卫生导报, 2025, 31(11): 1770-1774.
[5]	杨星王秋茹周雪. 脂蛋白a和载脂蛋白B联合维生素D检测对冠心病严重程度及短期预后的评估价值 [J]. 国际医药卫生导报, 2024, 30(8): 1238-1242.
[6]	张展李杏莫琳勤苏严琳孙艳彬. 结局引导的双心服务在冠心病不稳定型心绞痛患者PCI围手术期中的应用 [J]. 国际医药卫生导报, 2024, 30(4): 641-646.
[7]	高月郑华鹏. 血府逐瘀胶囊联合西医常规治疗对心绞痛患者的影响 [J]. 国际医药卫生导报, 2024, 30(24): 4202-4206.
[8]	张乐常小琪. Teach-back联合叙事护理在老年冠心病患者经皮冠状动脉介入术后的效果分析 [J]. 国际医药卫生导报, 2024, 30(19): 3337-3342.
[9]	沈沽灼陈艳丽李秀芬. 增强型体外反搏在心脏康复中的研究进展 [J]. 国际医药卫生导报, 2024, 30(12): 1937-1941.
[10]	叶凤翔刘栋涛范子晨. PCI术中应用药物涂层球囊对冠心病不稳定性心绞痛患者的临床疗效 [J]. 国际医药卫生导报, 2024, 30(1): 57-62.
[11]	莫琳勤李杏张展苏严琳孙艳彬. 以格林模式为框架的强化护理模式在冠心病不稳定型心绞痛患者中的实践研究 [J]. 国际医药卫生导报, 2023, 29(8): 1160-1166.
[12]	刘晓卉. 小剂量硝酸甘油联合氯吡格雷治疗冠心病心绞痛患者的疗效及安全性评价 [J]. 国际医药卫生导报, 2023, 29(4): 549-553.
[13]	何海燕芦菲. 尼可地尔联合水化预防冠状动脉介入术后对比剂肾病的临床疗效 [J]. 国际医药卫生导报, 2023, 29(24): 3645-3648.
[14]	刘朝阳周付娇. 甲状腺功能与冠心病患者病情进展的关联研究 [J]. 国际医药卫生导报, 2023, 29(18): 2601-2605.
[15]	李晶孙爱臣王桂玲任倩倩王丹. 多维化个体护模式在老年冠心病患者中的应用 [J]. 国际医药卫生导报, 2023, 29(12): 1729-1733.